188 related articles for article (PubMed ID: 24004183)
21. Concepts in use of high-dose methotrexate therapy.
Treon SP; Chabner BA
Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
[TBL] [Abstract][Full Text] [Related]
22. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
24. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
25. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
26. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use.
Snyder RL
Am J Health Syst Pharm; 2007 Jun; 64(11):1163-9. PubMed ID: 17519458
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.
Blay JY; Conroy T; Chevreau C; Thyss A; Quesnel N; Eghbali H; Bouabdallah R; Coiffier B; Wagner JP; Le Mevel A; Dramais-Marcel D; Baumelou E; Chauvin F; Biron P
J Clin Oncol; 1998 Mar; 16(3):864-71. PubMed ID: 9508167
[TBL] [Abstract][Full Text] [Related]
28. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.
Chan AJ; Rajakumar I
J Oncol Pharm Pract; 2014 Apr; 20(2):93-9. PubMed ID: 23698198
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
[TBL] [Abstract][Full Text] [Related]
30. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
32. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.
Barreto JN; Reid JM; Thompson CA; Mara KC; Rule AD; Kashani KB; Leung N; Larson TR; McGovern RM; Witzig TE; Barreto EF
Clin Transl Sci; 2022 Jan; 15(1):105-117. PubMed ID: 34378331
[TBL] [Abstract][Full Text] [Related]
35. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
36. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
[TBL] [Abstract][Full Text] [Related]
37. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
38. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
39. Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma.
Uluoğlu C; Oğuz A; Timlioğlu O; Biberoğlu G; Hasanoğlu A
Gen Pharmacol; 1999 Feb; 32(2):215-8. PubMed ID: 10188622
[TBL] [Abstract][Full Text] [Related]
40. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
